Announcements Trials

Browse Landscape

Phase

Phase NA 4 Phase 1 4 Phase 4 2 Phase 2/3 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 141 NIH 4 INDUSTRY 2 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Hyperplasia 1

Interventions

Capecitabine 28 apatinib 25 Oxaliplatin 24 Cisplatin 24 tislelizumab 23 Gemcitabine 23 Irinotecan 19 Paclitaxel 18 Carboplatin 18 Docetaxel 15 Bevacizumab 15 Fluorouracil 14 Drug Therapy 13 Cyclophosphamide 11 pembrolizumab 10 camrelizumab 10 Vinorelbine 9 Radiation 9 S 1 (combination) 8 Leucovorin 8 Cetuximab 8 toripalimab 7 sintilimab 7 Rituximab 7 Erlotinib Hydrochloride 7 pyrotinib 6 Gefitinib 6 Albumin-Bound Paclitaxel 6 fludarabine 5 anlotinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER_GOV × Metformin × Clear all

NCT01686126 2024-08-28

feMMe

Queensland Centre for Gynaecological Cancer

Phase 2 Active not recruiting

Endometrial Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡